Table 1. Recommendations for omalizumab treatment in CSU.

European Medicine Agency (EMA)	Food and Drug Administration (FDA)
Add-on therapy for the treatment of CSU in adults and	Additional treatment of CIU (150 or 300 mg s.c. every 4
adolescents (12 years and above, 300 mg s.c. every 4	weeks) in adults and adolescents (12 years of age and older)
weeks) with inadequate response to H1- antihistamine	who remain symptomatic despite
treatment	H1-antihistamine treatment
CIU: chronic inducible urticaria; CSU: chronic spontaneous urticaria; s.c.: subcutaneous.